{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:46:25Z","timestamp":1789386385809,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.parkreldis.2011.01.009","type":"journal-article","created":{"date-parts":[[2011,2,10]],"date-time":"2011-02-10T06:42:40Z","timestamp":1297320160000},"page":"260-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Dopamine agonist-triggered pathological behaviors: Surveillance in the PD clinic reveals high frequencies"],"prefix":"10.1016","volume":"17","author":[{"given":"A.","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Bower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.D.","family":"Fealey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"Josephs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Ahlskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.parkreldis.2011.01.009_bib1","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archneur.62.9.noc50009","article-title":"Pathological gambling caused by drugs used to treat Parkinson disease","volume":"62","author":"Dodd","year":"2005","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.parkreldis.2011.01.009_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.parkreldis.2005.06.005","article-title":"Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson\u2019s disease and multiple system atrophy","volume":"11","author":"Klos","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"10.1016\/j.parkreldis.2011.01.009_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0025-6196(11)60538-7","article-title":"Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease","volume":"84","author":"Bostwick","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.parkreldis.2011.01.009_bib4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.parkreldis.2007.04.004","article-title":"Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson\u2019s disease and multiple system atrophy","volume":"13","author":"McKeon","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"10.1016\/j.parkreldis.2011.01.009_bib5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/mds.20757","article-title":"Compulsive eating and weight gain related to dopamine agonist use","volume":"21","author":"Nirenberg","year":"2006","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.parkreldis.2011.01.009_bib6","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/mds.21611","article-title":"Pathological gambling in Parkinson\u2019s disease: risk factors and differences from dopamine dysregulation. An analysis of published case series","volume":"22","author":"Gallagher","year":"2007","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.parkreldis.2011.01.009_bib7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/WCO.0b013e32826fbc8f","article-title":"Medication-related impulse control and repetitive behaviors in Parkinson\u2019s disease","volume":"20","author":"Voon","year":"2007","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"10.1016\/j.parkreldis.2011.01.009_bib8","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00702-003-0027-5","article-title":"Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum","volume":"110","author":"Gerlach","year":"2003","journal-title":"J\u00a0Neural Transm"},{"issue":"6","key":"10.1016\/j.parkreldis.2011.01.009_bib9","first-page":"1111","article-title":"Function and therapeutic potential of the dopamine D3 receptor","volume":"192","author":"Sokoloff","year":"1998","journal-title":"C\u00a0R Seances Soc Biol Fil"},{"issue":"1","key":"10.1016\/j.parkreldis.2011.01.009_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0893-133X(98)00066-9","article-title":"Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons","volume":"20","author":"Gurevich","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"20","key":"10.1016\/j.parkreldis.2011.01.009_bib11","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A\u00a0five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 Study Group","volume":"342","author":"Rascol","year":"2000","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.parkreldis.2011.01.009_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ana.10609","article-title":"Slower progression of Parkinson\u2019s disease with ropinirole versus levodopa: the REAL-PET study","volume":"54","author":"Whone","year":"2003","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.parkreldis.2011.01.009_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00002826-200001000-00007","article-title":"A\u00a0randomized controlled trial comparing pramipexole with levodopa in early Parkinson\u2019s disease: design and methods of the CALM-PD Study. Parkinson Study Group","volume":"23","year":"2000","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1016\/j.parkreldis.2011.01.009_bib14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"issue":"3","key":"10.1016\/j.parkreldis.2011.01.009_bib15","first-page":"335","article-title":"Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson\u2019s disease","volume":"251","author":"Linazasoro","year":"2004","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.parkreldis.2011.01.009_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinthera.2005.12.003","article-title":"Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson\u2019s disease: a review of the literature","volume":"28","author":"Thobois","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.parkreldis.2011.01.009_bib17","series-title":"Parkinson\u2019s treatment guide for physicians","author":"Ahlskog","year":"2009"},{"issue":"1","key":"10.1016\/j.parkreldis.2011.01.009_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archneur.60.1.91","article-title":"Survival study of Parkinson disease in Olmsted County, Minnesota","volume":"60","author":"Elbaz","year":"2003","journal-title":"Arch Neurol"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802011000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802011000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:11:49Z","timestamp":1761178309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802011000125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1353802011000125"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2011.01.009","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dopamine agonist-triggered pathological behaviors: Surveillance in the PD clinic reveals high frequencies","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2011.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}